Kornimate/medical-research-clean huggingface dataset:
deep learning for the discrimination among different types of keratits: a nationwide study

Conditions: Keratitis; Automatic Judgement; Image

Summary: detecting the cause of keratitis fast is the premise of providing targeted therapy for reducing vision loss and preventing severe complications. due to overlapping inflammatory features, even expert cornea specialists have relatively poor performance in the identification of causative pathogen of infectious keraitis. in this project, the investigators aim to develop an automated and accurate deep learning system to discriminate among bacterial, fungal, viral, amebic and noninfectious keratitis based on slit-lamp images and evaluated this system using the datasets obtained from mutiple independent clinical centers across china.


Eligibility criteria:
inclusion criteria: slit-lamp images with sufficient diagnostic certainty and showing keratitis at the active phase. exclusion criteria: * poor-quality images * images presenting mixed infections (i.e., cornea infected by two or more causative pathogens)

Keywords: keratitis slit-lamp image deep learning
csa+atg+ava vs. csa+ava for the treatment of newly-diagnosed saa in the elderly

Conditions: Aplastic Anemia

Summary: this is a multicenter, prospective, randonmized study. our previous retrospective study showed that for saa patients who were intolerant to atg, csa+ eltrombopag (epag) had similar efficacy to csa+atg+epag. since the action mechanism of ava and epag is not exactly the same, and the metabolic level of the elderly is not the same as that of younger patients, it is unknown whether there are predictive factors of efficacy in the treatment of ava. we wondered whether csa+ava could achieve an efficacy similar to csa+atg+ava in the elderly. meanwhile, to explore the predictive factors of efficacy, to find out a safe and effective treatment strategy for the elderly.

aplastic anemia (aa) can be divided into severe aa (saa) and non-severe aa (nsaa), according to the severity of the disease. for saa patients with o condition of hematopoietic stem cell transplantation, guideline recommended ciclosporin a (csa) + anti-thymocyte immunoglobulin (atg) + thrombopoietin receptor agonists (tpo-ra) as the first-line therapy. our previous retrospective study showed that for saa patients who were intolerant to atg, csa+ eltrombopag (epag) had similar efficacy to csa+atg+epag. however, the adverse effects such as hepatotoxicity and gasrointestinal disorder limit its application in elderly saa.compared with epag, ava has no hepatotoxicity and less other adverse effects, but there was few studies for aa. our previous study demonstrated that ava was effective in 55% of refractory aa. since the action mechanism of ava and epag is not exactly the same, and the metabolic level of the elderly is not the same as that of younger patients, it is unknown whether there are predictive factors of efficacy in the treatment of ava. thus, we wondered whether csa+ava could achieve an efficacy similar to csa+atg+ava in the elderly.

Eligibility criteria:
inclusion criteria: 1. patients with newly diagnosed severe aplastic anemia, aged greater than 60 years. 2. patients met the diagnostic criteria of severe aplastic anemia (saa). 3. complete all screening assessments as outlined in the test protocol. 4. without or with no more than 1 month treatment of ciclosporine, tacrolimus, glucocortocoid, or tpo-ras. 5. agree to sign the informed consent form. exclusion criteria: 1. known diagnosis of congenital hematopoietic failure disorders (e.g. fanconi anemia) and other causes of cytopenia. 2. patients with uncontrolled bleeding and/or infection despite standard treatment. 3. patients with previous history of hematopoietic stem cell transplantation. 4. patients with previous history of thrombosis in 1 year. 5. patients with concurrent malignancy. 6. those who are considered unsuitable for enrollment by the investigator. 7. abnormal renal function: creatinine \> 1.2 normal upper limit, albumin \< 0.9 normal lower limit, or clcr \< 30 ml/min. 8. abnormal liver function: transaminase \> 2.5 normal upper limit, or tota bilirubin \> 2.5 normal upper limit. 9. patients with severe heart, liver or renal disease.
transcranial stimulation in motor stroke rehabilitation

Conditions: Stroke

Summary: patients were randomized in 3 groups: two intervent groups and a control group. the first group received two weeks of daily session of repetitive transcranial magnetic stimulation (rtms, 10 sessions) and, at least 6 months after, two weeks of daily transcranial direct current stimulation (tdcs, 10 sessions); the second group received 10 daily session of tdcs and, after at least 6 months, 10 sessions of rtms; the control group received 10 daily session of sham tdcs. physiatric evaluations (arat scale), neuropsychological assessment and erp (p300) were performed before (1 week) and after (1 week) the end of each treatment. furthermore, all patients underwent follow-up neuropsychological assessment 6 months after the end of each stimulation period and follow-up physiatric evaluation at 3 and 6 months after the end of each stimulation period.


Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke (\> 6 months from the accident) exclusion criteria: * general cognitive impairment (mini mental state examination \< 25), severe functional disability (barthel index \< 45), * psychiatric disorders, * degenerative neurological disorders, * epilepsy, * severe medical conditions, * having been implanted a drug infusion system, spinal/brain-stimulator, or endovascular coil

Keywords: rehabilitation non invasive brain stimulation
reliability and validity of outcome measures for phantom limb pain

Conditions: Phantom Limb Pain

Summary: phantom limb pain (plp) is experienced by 60-80% of all people who have had an amputation. this persistent pain condition can impact on independence, activities of daily living and overall quality of life. while there is some research into plp there is no consensus on appropriate outcome measures and there is (to our knowledge) neither guideline nor literature evidence on the reliability and validity of outcomes measures for this patient group. such measures are vital to the robust evaluation of any interventions and/or monitoring progression. the aim of the proposed study is to assess the reliability and validity of four self-report questionnaires (visual analog scale (vas) for pain, short form mcgill pain questionnaire 2 (sfmpq-2), trinity amputation and prosthetic evaluation scale (tapes), a health-related quality of life measure (eq-5d-l), a pain diary, a left/right limb judgement task (implicit motor imagery testing - imit) and the two-point discrimination (tpd)test. the data will be collated and statistically analysed to assess how stable each of the measures are over time (intra session reliability) and how each measure co-relates with the others (validity).


Eligibility criteria:
inclusion criteria: * age: ≥ 18 years at least six months post amputation (date of surgery) the amputation must be above wrist/ankle. are currently experiencing plp which has persisted for at least 3 months or more they rate their plp as ≥3 on a 0-10 scale on at least 2 days in the preceding week concomitant medications; exclusion criteria: * participating in any research trial of any intervention hypothesised to affect plp. currently under-going active prosthetic rehabilitation e.g. walking training sessions or upper limb rehabilitation sessions. any current non-prescribed substance dependency an inability to understand and follow basic instructions - both the two-point discrimination test and left/right limb judgement task requires the participant to follow basic/simple instructions. any person, otherwise eligible, who commences any treatment for plp (physical or pharmacological, prescribed or non-prescribed) will be withdrawn from the study.
the effectiveness of a health education intervention to reduce anxiety in quarantined covid-19 patients

Conditions: Health Education, COVID-19, Quarantine, Anxiety, Pandemic

Summary: we aimed to assess the impact of health education on the anxiety level of covid-19 patients during the isolation period.

this is a randomized controlled trial conducted between february 2021 and june 2021. patients tested positive for covid-19 with mild to moderate forms were randomized to education (n=267) or control (n=269). the education group received a phone health education session on day 1 (d1) following the diagnosis. the three components of the health education intervention were an explanation of the coronavirus disease, what to do in the event of complications, and the recommended preventive measures. the two groups received a telephone evaluation of their hospital anxiety and depression scores on (d1) and day seven d7 following the positive diagnosis. the primary outcome was the rate of anxiety reduction in each group at d7 based on a had-a score ≥ 8. secondary outcomes were the rate of anxiety reduction at d7 based on a had-a score ≥ 11, the percentage of people complying with isolation and the scores of adherence to preventive measures during the isolation in each group.

Eligibility criteria:
inclusion criteria: * patients diagnosed with covid-19 after positive pcr or positive antigen rapid test, over 18 years of age, who did not require hospitalization exclusion criteria: * patients not reachable at the first day phone call of the diagnosis and patients unable to answer the telephone questionnaire due to their cognitive state.
a multicenter, randomized, double-blind, double-dummy comparative trial of azithromycin sustained release versus 3-day azithromycin for the treatment of strep throat in adolescents and adults

Conditions: Pharyngitis; Tonsillitis

Summary: to determine if a single 2.0-g dose of azithromycin sr is at least as effective as a 3-day course of azithromycin (500 mg once daily for 3 days) when used to treat adolescents and adults with strep throat, and to assess efficacy and safety for both treatment regimens.


Eligibility criteria:
inclusion criteria: * patients with evidence of acute group a beta-hemolytic streptococcus (gabhs) pharyngitis/tonsillitis and a positive rapid antigen detection test or positive culture of the pharynx or tonsils for gabhs exclusion criteria: * patients were excluded if they had treatment with any systemic antibiotic within the previous 7 days, a history of rheumatic fever, a peritonsillar abcess, or were known carriers of gabhs.
a study of dmot4039a in participants with unresectable pancreatic or platinum-resistant ovarian cancer

Conditions: Ovarian Cancer

Summary: this multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of dmot4039a in participants with unresectable pancreatic or platinum-resistant ovarian cancer. cohorts of participants will receive multiple ascending intravenous doses of dmot4039a.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status 0 or 1 * histologically documented, incurable, locally advanced or metastatic disease for which no standard therapy exists, consisting of one of the following: unresectable pancreatic ductal adenocarcinoma or platinum-resistant ovarian cancer * measureable disease, defined as at least one bi-dimensionally measurable non-lymph node lesion greater than or equal to (\>/=) 1 centimeter (cm) in long-axis diameter on spiral computed tomography (ct) scan or at least one bi-dimensionally measurable lymph node measuring \>/= 1.5 cm in short-axis diameter on spiral ct scan * adequate hematological, renal and liver function exclusion criteria: * treatment with anti-tumor therapy, including chemotherapy, biologic, experimental or hormonal therapy, within 4 weeks prior to day 1 * known active infection * current grade \>/= 2 toxicity (except for alopecia, anorexia and fatigue) from prior therapy or grade \>/= 2 neuropathy * untreated or active cerebral nervous system metastases * pregnant or breastfeeding women
certain maternal antibodies in relation to doppler in hypertension with pregnancy

Conditions: Pre-Eclampsia

Summary: relation of certain maternal serum antibodies to doppler changes will be studied in cases suffering from hypertension with pregnancy.

assessment will be done for maternal serum anti-beta 2 glycoprotein 1 antibodies and anticardiolipin antibodies in cases of preeclampsia after 32 weeks of pregnancy. in addition, fetal doppler changes will be assessed.

Eligibility criteria:
inclusion criteria: * pregnant women 32 weeks or more gestational age * pre-eclampsia * singleton pregnancy exclusion criteria: * intrauterine fetal death * fetus with apparent congenital anomalies * pregnant females with other medical disorders * history of essential hypertension. * history of antepartum hemorrhage. * history of rupture of membranes.
prospective evaluation of a palato-pharyngeal implant system (ppis) obstructive sleep apnea syndrome (osas)

Conditions: Snoring; Obstructive Sleep Apnea

Summary: prospective evaluation of a palato-pharyngeal implant system (ppis) for the treatment of snoring and obstructive sleep apnea syndrome (osas): a pilot study.

the clinical study is designed as single center, prospective, non-randomized and non-blinded clinical study. since the surgical procedure is independent of the population a single center study is applied. a double-blind study is not possible considering the implantation procedure with the surgeon always knowing if the device is set. therefore, the study is designed to be non-randomized and non-blinded as a pilot trial. to reduce bias and other influences of single surgeon skills a principal investigator and one investigator are part of the clinical study. further, subjects with previous treatments such as pillar implant or previous airway surgery other than nasal, adenoid, tonsil or uppp are excluded from the clinical study. a double-blind study is not possible considering the implantation procedure with the surgeon always knowing if the device is set. therefore, the study is designed to be non-randomized and non-blinded as a pilot trial.

Eligibility criteria:
inclusion criteria: * • socially disturbing snoring and obstructive sleep apnea syndrome with ahi≥10/h * predominantly retropalatal obstructions established either by: * drug-induced sedation nasendoscopy * or apneagraph ≥60% (optional) * or successful application of the velumount palatal device (optional) * findings for predominantly retropalatal obstructions in ent-examination: * no tonsils or tonsils grade i * normal finding of larynx and tongue base, no omega-shaped epiglottis * no lingual tonsil hypertrophy * asa (american society of anaesthesiology, 1963) classes i or ii * body mass index (bmi) \< 30 kg/m2 * age \> 18 yrs * fix bed partner * ability to read and understand the patient's information exclusion criteria: * • previous pillar implants * medartis palatinal implant (from previous phase i study) * previous airway surgery other than nasal, adenoid, tonsil or uppp * presence of other sleep disorders * psychiatric disorders * neurological disorders (e.g. cerebrovascular injury) * dysmorphia of the cranial skeleton * pregnancy or breastfeeding * known hypersensitivity to nitinol * participation in another clinical study * recurrent tonsillitis with prescription of antibiotics during the last 2 years (≥3x/year) * omega-shaped epiglottis * lingual tonsil hypertrophy * kinking of the internal carotid artery

Keywords: snoring, obstructive sleep apnea
china ovarian cancer brca testing study

Conditions: Ovarian Cancer

Summary: this is a prospective, multi-center, observational study, the primary objective is to evaluate the prevalence of gbrca/sbrcam in newly diagnosed ovarian cancer patients and explore ovarian cancer treatment outcomes of different brcam status

this is a prospective, multi-center, observational study that will enroll consecutive patients with a confirmed diagnosis of epithelial ovarian cancer, fallopian tube, or peritoneal cancer and who consent to a blood draw, a tissue sample analysis, and follow up for collection of data. 900 newly diagnosed ovarian cancer patients will be enrolled and evaluated for breast cancer susceptibility genes brca1 and brca2 germline and somatic mutations (brcam). approximately 170 brcam positive patients and 170 negative patients will be followed in the follow-up period. this study aims to answer very important questions regarding the prevalence of gbrcam and sbrcam in a population of newly diagnosed ovarian cancer patients, and the relationship of these mutations to patient treatment and clinical outcomes. these answers may be extremely helpful in the counseling and treatment of genetic risk in these populations and may aid in making treatment decisions in the future.

Eligibility criteria:
inclusion criteria: * be able and willing to sign the informed consent form (icf) * female aged 18 years or over * have histologically confirmed new diagnosis of federation of gynecology and obstetrics (figo) stage iii or iv ovarian epithelial, primary peritoneal, or fallopian tube cancer made by one or more of the following: * standard staging laparotomy including bilateral salpingo-oophorectomy, omentectomy, and lymph node sampling and debulkingand/or * surgical resection and radiographic evidence consistent with stage iii or iv ovarian cancer * biopsy with radiographic evidence consistent with stage iii or iv ovarian cancer * have availability of paraffin-embedded archivedtumor tissue block (preferred) or,if a block is not possible, a minimum of twenty 5-μm unstained sections. (tumor tissue should be archived at diagnosis. 10 slides is utilized for sbrca testing after the enrolment. another 10 slides is utilized for exploratory evaluation of hrr gene mutations in a retrospective way.) * have a diagnosis that is within 60 days of informed consent exclusion criteria: * have a diagnosis of additional concurrent malignancies or previous diagnosis of another malignancy with current evidence of residual disease * have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the investigator, would make the patient inappropriate for enrollment in this study * be currently participating in any other clinical trial for first-line treatment of ovarian cancer * be a patient who, in the judgement of the investigator, would be inappropriate for enrollment in this study

Keywords: brca mutation
synergic effects of ultrasound and laser on the pain relief and functionality

Conditions: Osteoarthritis

Summary: there are several therapeutic effects of the ultrasound (us) or low level laser therapy (lllt), including pain relief, increase of microcirculation, modulation of inflammatory response and accelerated tissue repair. the investigators hypothesis was that a combination of us, lllt and therapeutic exercise may maximize clinical outcome.

patients with pain, especially chronic pain, avoid movements. this is turn results in a gradual impairment of their physical condition, reducing, for example, strength, flexibility, physical functionality and occupational activity. to performed physical treatments, a prototype device was development. the device includes four diode laser beams (808 nm) around of the one ultrasound transducer.

Eligibility criteria:
inclusion criteria: * caucasian women * aged between 60 and 80 years * hand osteoarthritis * knee osteoarthritis exclusion criteria: * psychiatric disorder, * neurological disease * metabolic disease * pulmonary disease * cardiac disease, * thrombosis * cancer.

Keywords: ultrasound laser therapeutic exercise rehabilitation osteoarthritis
clinical and immunological long-term follow-up of patients with pemphigus included in the "rituximab 3" trial

Conditions: Autoimmune Diseases

Summary: pemphigus is an autoimmune disease specific to the skin and mucous membranes characterized by the production of igg4 isotype autoantibodies (ac) directed mainly against two proteins involved in interkeratinocyte adhesion: desmoglein 1 (dsg1 ) and desmoglein 3 (dsg3) (1-3). the binding of auto-ac on these proteins disrupts their adhesion function, resulting in inter-keratinocyte dysjunction called "acantholysis" responsible for the formation of intraepidermal bubbles. treatment of pemphigus is typically based on systemic corticosteroids. high doses are usually necessary because of the frequent cortico-resistance of the disease. in recent years, several studies have focused on the treatment of pemphigus with anti-cd20: rituximab. the "ritux 3" study (nct00784589), a randomized, multicentre, randomized, non-blind clinical trial involving 90 patients, found that the use of rituximab as first-line therapy in combination with short corticosteroid therapy was extremely effective and that cortisone sparing was thus obtained limited the occurrence of side effects of treatment. on the other hand, this study showed that the 2 rituximab maintenance infusions of 500 mg to m12 and m18 allowed the maintenance of a high rate of complete remission up to the 3rd year of follow-up. questions remain to explain the long-term action of rituximab, in particular that of the evolution of these auto-reactive b cells (specific dsg) away from lymphocyte reconstitution b, as well as the evolution of auto-ac. anti-dsg and total igg cas, so as to ensure that the disappearance of the auto-reactive compartment is not accompanied by a long-term overall immunosuppression (and therefore a possible risk of infection). the immunological changes induced in the long term as well as the precise mechanism of action of these treatments and particularly rituximab which allows a complete remission 5 years after treatment in many patients remain little known.


Eligibility criteria:
inclusion criteria: * patient included in the rituximab 3 study * major patient who has read and understood the newsletter and signed the consent form exclusion criteria: * person deprived of liberty by an administrative or judicial decision * person placed under the safeguard of justice * person under tutorship or curators * pregnant or lactating woman
collection of anatomical and reference data for development of a novel non-invasive lung hydration status technology

Conditions: Healthy

Summary: this study will be conducted to collect anatomical data in an ambulatory healthy population to aid in the development of a novel non-invasive technology to assess changes in lung hydration status. it will also help in developing reference ranges of lung hydration status in healthy subjects and their associated changes with time.


Eligibility criteria:
inclusion criteria: * subjects \> 30 years of age * subjects who are ambulatory not requiring assistance for ambulation * subjects who have been informed of the nature of the study and agree to its provisions and have provided written informed consent as approved by the irb exclusion criteria: * subjects with an active implantable medical device not cleared for use with the imed-4 in the imed- 4 investigators brochure. * subjects who are pregnant or lactating or who have been pregnant within the past three months * subjects who have a measured temperature of \>38° c at the time of screening * subjects who have tattoos and/or non-intact skin on the back in the electrode patch placement region * subjects who have had a past serious allergic reaction to adhesives * patients who decline to have their backs photographed with the imed-4 device in position * subjects who have poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectance, etc.)

Keywords: chf heart failure